Skip to content
CompletedPhase 4

Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy

NCT01870219 · Inonu University

Closed to entry
Status
Not accepting participants
Phase 4
Phase
24
Target enrolment
1
Study sites
Outside the US

What it is testing

Summary

The aim of this study was to evaluate the effect of sevoflurane or ketamine on the QTc and Tp-e interval during in patients with major depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Evaluation Of QT interval

    Measured over 10 minutes

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years to 60 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Unpremedicated * American Society of Anesthesiologists (ASA) I-II the patients * Major depressions patients scheduled for ECT sessions Exclusion Criteria: * pregnant * with permanent pacemakers, * diabetes mellitus, * atrial fibrillation, * electrolyte imbalance, * patients taking antiarrhythmics and β-blockers.

Where

1 study site

FacilityCityRegionCountry
Turgut Ozal Medical CenterMalatyaTurkey (Türkiye)

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT01870219 on ClinicalTrials.gov →

Last updated in the registry 2013-06-06. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits